ClinicalTrials.gg
Not yet recruitingNCT07554573ABCD RTUpdated Sep 30, 2026

Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)

A Phase 3 interventional study of Radiation Therapy and Standard of Care Radiation Therapy in Breast Cancer, sponsored by NRG Oncology. Not yet recruiting. Open to female participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Primary conditionCarcinoma, Intraductal, NoninfiltratingRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Intraductal, Noninfiltrating
Why
  1. The study's title name Carcinoma, Intraductal, Noninfiltrating, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by NRG Oncology · Phase 3, Interventional, and Prevention

Updated Sep 30, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,270
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
Female
01

Study summary

NRG-CC016 is being done to determine if omission of radiation therapy (RT) for patients with biosignature Low Risk (DCISionRT score less than 2.8) DCIS yields no clinically meaningful increase ipsilateral breast recurrence (IBR) compared to those treated with RT (Cohort A).

Read the detailed description

Current DCIS treatment decisions rely on clinical-pathologic criteria that have remained unchanged for over 50 years. Even in favorable patients, RT provides an absolute benefit (\~8%), which is considered clinically meaningful.

However, DCISionRT retrospective data suggests that approximately 37% of patients (Low Risk) may safely omit RT with less than 1% absolute difference in IBR. This could impact around 22,470 women annually in the US. Further, approximately one-third of Grade 3 DCIS patients (who have biosignature Low Risk scores) may also safely omit RT.

From a number-needed-to-treat (NNT) perspective, RTOG 9804 results suggest that to prevent an IBR the NNT ≈ 13. In contrast, the DCISionRT data for biosignature Low Risk, the NNT ≈ 125. This represents a major shift in treatment value.

In addition, shorter RT regimens have increased RT utilization, raising concerns about overtreatment. Biosignature-guided care could better balance overtreatment versus undertreatment.

For high-risk DCIS, there have been no NCTN trials in over 20 years (last being ECOG 5194). NRG CC016 would be the first trial since then to include high-risk DCIS by both clinical-pathology and biosignature (score greater than 2.8 - Cohort B) criteria and determine the clinical utility of biosignature risk categorization over patient age and tumor grade, size and hormone receptor status. It will also prospectively assess outcomes for the subsets of Elevated Risk (\~40% of DCIS) and Residual Risk (\~20% of DCIS) patients treated with standard-of-care breast RT, with anticipated 10-year IBR rates of 5% and 15%, respectively.

The study addresses multiple critical gaps:

  • First prospective assessment of a biosignature to determine its clinical utility in risk assessment for DCIS.
  • Determine if biosignature Low Risk patients gain no clinically meaningful benefit from RT.
  • Prospective assessment of outcomes in Elevated and Residual Risk groups.
  • Evaluation of boost benefit in higher-risk subgroups.
  • Evaluation of patient-reported outcomes including worry and quality of life (Section 11.1) for DCIS.

This trial will randomize Low Risk biosignature patients to test the non-inferiority of RT-omission and prospectively determine outcomes in Elevated Risk and Residual Risk biosignature groups treated with RT. If published retrospective data are reproduced prospectively here, this would:

  • Redefine standard-of-care treatment for DCIS through use of a biosignature.
  • Enable safe omission of RT in selected patients (Low Risk) regardless of clinical-pathologic criteria with excellent outcomes.
  • Identify a subset of DCIS (Elevated Risk) with similar excellent outcomes following breast RT.
  • Identify a specific subset of DCIS (Residual Risk) in need of additional intervention.
  • Represent the first prospective assessment of a radiation-specific biosignature in oncology.
02

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Radiation Therapy
  • Ductal Carcinoma in Situ (DCIS)
03

In context

Carcinoma, Intraductal, Noninfiltrating Reclassified

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

This study's planned enrollment of 5,270 is above the median of 66 across 209 interventional studies indexed under Carcinoma, Intraductal, Noninfiltrating.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Lead sponsor

NRG Oncology is the lead sponsor of 72 studies on the registry; 25 are open to participants now.

Compared within Carcinoma, Intraductal, Noninfiltrating, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • The patient or a legally authorized representative must provide study-specific prior to Step 1/Registration and, for patients treated in the U.S., authorization permitting release of personal health information.

Breast and Disease Assessment

  • The patient must be female and greater than or equal to 30 and less than or equal to 85 years of age. (Note: The DCISionRT test is validated only in women between the ages of 30 and 85.)
  • The patient must have a diagnosis of DCIS less than or equal to 6 cm. (Note: The DCISionRT test is validated only in women with DCIS less than or equal to 6 cm.)
  • The patient must have an performance status of less than or equal to 2 (or greater than or equal to 50%).
  • The patient must have had a bilateral mammogram within 6 months prior to registration.
  • The patient must have undergone breast conserving surgery with negative surgical margins (greater than or equal to 2 mm). Margin status is assessed on lumpectomy specimen and/or additional margins as determined by the local pathologist. If pathologic examination demonstrates DCIS less than 2 mm from resection edge, additional excisions may be performed to obtain clear margins. Patients with lobular carcinoma in situ (LCIS), atypical lobular hyperplasia (ALH), and/or atypical ductal hyperplasia (ADH) are eligible regardless of margins for these histologies.
  • The patient must have no suspicious unresected microcalcification, densities, or palpable abnormalities (in the ipsilateral or contralateral breast) unless biopsied and found to be benign.
  • The interval between the last surgery for DCIS (including re-excision of margins) and registration must be no more than 70 days
  • The following staging criteria must be met postoperatively according to AJCC 8th edition criteria:
  • Primary tumor must be pTis
  • Patients must be cN0 (by physical exam and/or imaging)
  • Axillary surgery staging with sentinel node and/or axillary node dissection is not required. If surgical axillary staging was performed, ipsilateral nodes must be pN0. (Patients with pathologic staging of pN0 (i+) or pN0)(mol+) are NOT eligible.
  • DCIS may be of any grade (1-3).
  • The DCIS must be tested for estrogen receptor (ER) and progesterone receptor (PgR) status, either on an initial core biopsy or surgical specimen, by current ASCO/CAP Guideline Recommendations for hormone receptor testing. Any ER and/or PgR receptor status is eligible.
  • Participants must have unilateral DCIS diagnosed within 4 months of registration without a history of prior ipsilateral or contralateral DCIS or invasive breast cancer.
  • DCISionRT result must have been either previously obtained or the patient has consented to submission of specimen for centralized testing by PreludeDx.
  • The patient must have recovered from surgery with the incision well healed and no signs of infection.
  • The patient must have no to standard-of-care breast radiotherapy (i.e., active collagen-vascular disease, scleroderma, prior breast/chest radiotherapy).

Co-morbid and Other Conditions

  • Patients of must have a negative pregnancy test within 14 days of registration, have no intention of becoming pregnant for 120 days following registration and be willing to use highly effective if randomized to RT from registration until 1 month after completion of RT.
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the treatment regimen are eligible for this trial.
  • If germ-line testing performed, results must be reviewed and indicate no pathogenic or likely pathogenic variants associated with increased breast cancer risk. (Variants of unknown significance are acceptable.)

Medications

  • Patients must discontinue hormone replacement therapy, including estrogens or progesterone formulations prior to study entry. Low-dose vaginal estrogen creams, tablets, rings, or IUDs are allowed. For patients treated with anti-endocrine therapy as chemoprevention for the development of breast cancer, anti-endocrine therapy must have been discontinued greater than 6 months prior to the diagnosis of DCIS.
  • anti-endocrine therapy is a standard treatment option for ER or PgR positive DCIS. Patients may not have a history of taking oral anti-endocrine therapy (SERMS, SERDS, or aromatase inhibitors) prior to DCIS diagnosis. Adjuvant anti-endocrine therapy for DCIS may not be initiated prior to DCISion RT testing.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5,270 participants (estimated)

Study arms

  • Active comparator
    Cohort A Arm 1, Breast Radiation Therapy

    Radiation therapy to breast for patients with DCISionRT score less than or equal to 2.8.

    Radiation: Radiation Therapy

  • Active comparator
    Cohort A Arm 2, No Breast Radiation Therapy

    No radiation therapy to breast for patients with DCISionRT score less than or equal to 2.8.

    Other: No Intervention

  • Other
    Cohort B

    Patients with DCISionRT score greater than 2.8.

    Radiation: Standard of Care Radiation Therapy

Interventions

  • RadiationRadiation Therapy

    Post-lumpectomy RT will be external beam radiation to the whole breast ± boost (sequential or integrated) or Partial Breast Irradiation (PBI). RT must begin within 112 days of the last breast cancer surgery (lumpectomy or re-excision of margins).

  • RadiationStandard of Care Radiation Therapy

    Patients will continue treatment with standard of care breast radiation therapy at the investigator's discretion.

  • OtherNo Intervention

    No intervention.

06

What researchers measure

Primary outcomes

  1. Time to Ipsilateral Breast Recurrence (IBR) in Cohort A patients

    Cumulative incidence of IBR.

    Time frame: 10 years

Secondary outcomes

  1. Time to IBR in Cohort B patients

    Cumulative incidence of IBR evaluated separately for Elevated Risk patients (defined as DCISionRT score \> 2.8, excluding score of 9.2) and Residual Risk patients (defined as DCISionRT score = 9.2).

    Time frame: 10 years

  2. Time to IBR in the subset of Cohort A and Cohort B patients with discordant clinical-pathology and biosignature risk categories

    Cumulative incidence of IBR evaluated separately for the subsets of Cohort A patients with high-risk clinical-pathologic features (age \< 50 or Grade 3 disease or ER- PR-negative or tumors \> 2.5 cm in size) and for Cohort B subsets of Elevated Risk and Residual Risk patients , with low-risk clinical-pathologic features (Grade 1-2, tumor ≤ 2.5 cm, ER- and/or PR-positive, age ≥ 50)

    Time frame: 10 years

  3. Time to invasive IBR

    Cumulative incidence of invasive IBR in Cohort A and Cohort B patients

    Time frame: 10 years

  4. Time to IBR-DCIS

    Cumulative incidence of IBR-DCIS in Cohort A and Cohort B patients

    Time frame: 10 years

  5. Breast cancer-free interval (BCFI)

    Cumulative incidence of BCFI events in Cohort A and Cohort B patients

    Time frame: 10 years

  6. Time to contralateral breast cancer

    Cumulative incidence of contralateral breast cancer events in Cohort A and Cohort B patients

    Time frame: 10 years

  7. Overall survival

    Percentage of patients alive in Cohort A and Cohort B patients

    Time frame: 10 years

  8. Ipsilateral mastectomy events

    Cumulative incidence of Ipsilateral mastectomy events in Cohort A and Cohort B patients

    Time frame: 15 years

  9. Patient-reported worry about recurrence

    Patient-reported worry about recurrence as measured by Cancer Worry Scale in Cohort A and Cohort B (evaluated separately for Elevated and Residual Risk) patients

    Time frame: 1 year

  10. Time to subsequent breast events (SBE)

    Cumulative incidence of SBE events in Cohort B patients who initiate anti-endocrine therapy

    Time frame: 10 years

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Jul 2039, 150 months later.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jan 2027, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
Apr 28, 2026
StartEst.
Jan 30, 2027was Jun 2026
Primary completionEst.
Jul 31, 2039
CompletionEst.
Jul 31, 2048
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 30, 2026→Jan 30, 2027
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Start date Jun 30, 2026→Jan 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07554573
Lead sponsor
NRG Oncology
Responsible party
Sponsor
First posted
Apr 28, 2026
Start date
Jan 30, 2027 (estimated)
Primary completion
Jul 31, 2039 (estimated)
Completion
Jul 31, 2048 (estimated)
Last update
Sep 30, 2026

Study contacts

Director Regulator y Affairs
Contact
langerj@nrgoncology.org
412-339-5300

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion